|Awarded On||August 18, 2021|
|Title||Antibody-Drug Conjugate Combination Treatment for Targeting Colorectal Cancer Cell Plasticity|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Kendra Carmon|
*Pending contract negotiation
Drug resistance, metastasis, and tumor relapse continue to be leading causes of colorectal cancer (CRC)-related deaths. Current therapies only provide a limited increase in survival to the subset of advanced CRC patients that respond, demonstrating the need for innovative therapeutic strategies to improve outcome. Cancer stem cells (CSCs) are a subpopulation of tumor cells shown to be major drivers of tumor growth, metastasis, and relapse. Therefore, an effective cancer treatment could be one that destroys CSCs. LGR5 is a protein highly upregulated in CRC with low expression in normal healthy tissues and is found on the surface of CSCs. We generated anti-LGR5 antibody-drug conjugates (ADCs) ...